Urology and Andrology Department, Elaj Medical Centres, Jeddah, Saudi Arabia.
King's College Hospital, London, UK.
BJU Int. 2018 Nov;122(5):889-897. doi: 10.1111/bju.14401. Epub 2018 Jun 14.
To compare serum testosterone response and symptom improvement in men with hypogonadism in response to treatment with clomiphene citrate (CC), human chorionic gonadotropin (hCG), or a combination of both therapies.
A total of 282 men with hypogonadism, wishing to preserve their fertility, were randomized to one of three treatment arms: CC 50 mg (n = 95); 5000 IU hCG injections twice weekly (n = 94); or a combination of both therapies (CC + hCG; n = 94). All participants had complete medical history and had undergone thorough physical examination, including body mass index (BMI) assessment. Laboratory tests included serum total testosterone and glycated haemoglobin (HbA1c) measurements. Quantitative Androgen Deficiency in the Aging Male (qADAM) questionnaire scores were also recorded. Morning samples of total serum testosterone levels were assessed at three time points: baseline, 1 and 3 months.
Testosterone levels increased at 1 and 3 months in all three groups. The mean baseline testosterone level was 2.31 ± 0.66 nmol/L, BMI was 30.8 ± 6.2 kg/m , and qADAM score was 20.5 ± 3.8. Testosterone levels increased in all groups at all time points, with a final mean value of 5.17 ± 1.77 nmol/L (223% increase) with no statistically significant difference among the groups. qADAM scores had increased in all groups at 1 month (CC group: 6.36; hCG group: 5.08; CC + hCG group: 7.26) and at 3 months (CC group: 12.73; hCG group: 11.82; CC + hCG group: 15.13) with a significant difference in intergroup analysis for the CC + hCG group compared with the other two groups (P < 0.01).
All three treatments were equally effective in restoring testosterone levels. Single-agent CC is simple, cheap and may be used as treatment for hypogonadism when maintenance of fertility is desired. This approach seems to be as effective as either hCG alone or a combination of hCG and CC.
比较氯米芬(CC)、人绒毛膜促性腺激素(hCG)或两者联合治疗对低促性腺激素血症男性的血清睾酮反应和症状改善。
共有 282 名希望保留生育能力的低促性腺激素血症男性患者被随机分为三组治疗:CC 50mg(n=95);每周两次注射 5000IU hCG(n=94);或两种疗法联合(CC+hCG;n=94)。所有参与者均接受完整的病史和全面的体格检查,包括体重指数(BMI)评估。实验室检查包括血清总睾酮和糖化血红蛋白(HbA1c)测量。还记录了定量雄激素缺乏在老年男性(qADAM)问卷评分。在三个时间点评估总血清睾酮水平的清晨样本:基线、1 个月和 3 个月。
三组患者的睾酮水平在 1 个月和 3 个月时均升高。平均基线睾酮水平为 2.31±0.66nmol/L,BMI 为 30.8±6.2kg/m2,qADAM 评分为 20.5±3.8。所有组在所有时间点的睾酮水平均升高,最终平均值为 5.17±1.77nmol/L(223%增加),组间无统计学差异。所有组在 1 个月时 qADAM 评分均升高(CC 组:6.36;hCG 组:5.08;CC+hCG 组:7.26)和 3 个月时(CC 组:12.73;hCG 组:11.82;CC+hCG 组:15.13),CC+hCG 组与其他两组相比,组间分析差异有统计学意义(P<0.01)。
三种治疗方法在恢复睾酮水平方面同样有效。单一药物 CC 简单、便宜,当需要维持生育能力时,可作为低促性腺激素血症的治疗方法。这种方法似乎与单独使用 hCG 或 hCG 和 CC 联合使用一样有效。